Determinatin of captopril in biological fluids by gas-liquid chromatography

Matsuki, Yasuhiko; Fukuhara, Katsuharu; Ito, Tomiharu; Ono, Hiroshi; Ohara, Naoki; Yui, Tohru; Nambara, Toshio

doi:10.1016/s0021-9673(00)88428-9

Cited by 54 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cohen et al (1982) reported that a modified electron-impact gas-liquid chromatography-selected ion monitoring mass spectrometric method could also be used for analysis of captopril. The captopril-NEM derivative can also be converted to a hexafluoropropanyl ester instead of the methyl ester, which is followed by gas-chromatography with detection by electron capture (Bathala et al 1984), flame photometry (Matsuki et al 1980), a nitrogensensitive detector (Mantyla et al 1984), or selected-ion monitoring (Drummer et al I 984b;Matsuki et al 1982). The lower limits of quantitation of captopril and its disulphide metabolites by gas chromatography-electron capture are comparable to those for GC/MS, whereas the limit of sensitivity of gas chromatography-flame photometry is only in the milligram per litre range, which is not sufficiently sensitive for human blood concentration studies.…”

Section: Assay Methodsmentioning

confidence: 99%

Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases

Duchin

McKinstry

Cohen

et al. 1988

Clinical Pharmacokinetics

130

View full text Add to dashboard Cite

Captopril, the first orally active inhibitor of angiotensin-converting enzyme, is used widely in the treatment of hypertension and congestive heart failure. The pharmacokinetics of this agent have been studied extensively in healthy subjects and in patients with hypertension, congestive heart failure, and chronic renal failure. Captopril contains a sulphydryl group and binds readily to albumin and other plasma proteins. The drug also forms mixed disulphides with endogenous thiol-containing compounds (cysteine, glutathione), as well as the disulphide dimer of the parent compound. These components in blood and urine are measured collectively as total captopril. Because of the reversibility of the formation of these inactive disulphides, total captopril may serve as a reservoir of the pharmacologically active moiety, and thus contribute to a duration of action longer than that predicted by blood concentrations of unchanged captopril. To measure free or unchanged captopril concentrations, a chemical stabiliser must be added to the biological samples to prevent the formation of captopril disulphides ex vivo. In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively. The elimination half-life of unchanged captopril was approximately 2 hours. The primary route of elimination of captopril is the kidney. The renal clearance of unchanged captopril exceeds the glomerular filtration rate, due to active tubular secretion of the drug. In healthy subjects, about 70 to 75% of an oral dose is absorbed and the bioavailability of captopril is approximately 65%. Peak blood concentrations are reached about 45 to 60 minutes after oral administration. The bioavailability of captopril is not altered by age or concomitant medications including diuretics, procainamide, allopurinol, cimetidine or digoxin. However, the co-administration of food or antacids, or probenecid with captopril has been shown to diminish the bioavailability of the latter and decrease its clearance, respectively. The decreased bioavailability of captopril when taken with meals does not significantly alter clinical responses to the drug. Over a wide range of oral (10 to 150 mg) and intravenous doses (2.5 to 10 mg) captopril had linear kinetics in healthy volunteers. In healthy subjects with normal renal function and patients with congestive heart failure given captopril 3 times daily, blood concentrations of total captopril accumulated, whereas those of unchanged captopril did not. Severe renal insufficiency was associated with an accumulation of both unchanged and total captopril.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

Section: Assay Methodsmentioning

confidence: 99%

Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases

Duchin

McKinstry

Cohen

et al. 1988

Clinical Pharmacokinetics

130

View full text Add to dashboard Cite

show abstract

“…Captopril has been determined by several methods, including gas chromatography (GC) [2], gas chromatography-mass spectrometry (GC-MS) [3,4], highperformance liquid chromatography (HPLC) [5][6][7][8][9][10][11] and liquid chromatography-mass spectrometry (LC-MS) [12]. However, the GC method is limited by sensitivity and the GC-MS or LC-MS methods may not be widely accessible.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous determination of captopril and hydrochlorothiazide in human plasma by reverse-phase HPLC from linear gradient elution

Huang

Yang

et al. 2006

Journal of Pharmaceutical and Biomedical Analysis

136

View full text Add to dashboard Cite

“…To assure the quality of CAP-containing pharmaceutical formulations, several methods have been reported for its determination, including fluorimetric methods (Imai, Toyoka, and Watanabi 1983;Cavrini et al 1988;Al-Ghannam, El-Brashy, and Al-Farhan 2002;Chen and Cai 2003), electrochemical methods (Mohamed, Aboul-Enein, and Gad-kariem 1983;Passamonti, Bartocci, and Pucciarelli 1987;Fraga et al 1998;Passamonti et al 1991;Pimenta, Araújo, and Montenegro 2001;Siangproh, Ngamukot, and Chailapakul 2003;Stefan, Hassan, and Aboul-Enein 2003), AAS (El Walily et al 1999;El Reis, Attia, and Kenawy 2000), chemiluminescence (Xinrong et al 1995;Zhang et al 1995Zhang et al , 1996Economou et al 2002), spectrophotometric methods (Shama, El-Sayed Amin, and Omara 2006;Basavaiah and Nagegowda 2004), capillary electrophoresis (Hillaert and Van den Bossche 1999), and chromatography (Matsuki et al 1980;Drummer, Jarrott, and Louis 1984;Ito et al 1987;Lin Ling et al 1989; Lin Baeyens 1990, 1991;Jankowski et al 1995;Liu et al 1995;Sypniewski and Bald 1996;Kok et al 1997;Ouyang et al 1999;Rao et al 2000;Mirza and Tan 2001). Flow-injection (FI) analysis is a well-established analytical technique that has advantages for routine analysis and quality-assurance control.…”

Section: Introductionmentioning

confidence: 99%

Flow-Injection Spectrophotometric Determination of Captopril Exploiting Silver Chloranilate Solid-Phase Reactor

et al. 2009

View full text Add to dashboard Cite

A novel, simple, and rapid flow-injection method for the spectrophotometric determination of captopril in pharmaceutical products, using a solid-phase reactor with silver chloranilate (Ag 2 C 6 Cl 2 O 4 ) immobilized in a polyester resin, is presented. This method explored the formation of an insoluble salt between Ag(I) and captopril in the solid-phase reactor, releasing chloranilate anion (C 6 Cl 2 O 2À 4 ). Then, this anion reacted with ferric ions to produce a complex, FeC 6 Cl 2 O þ 4 , which was monitored spectrophotometrically at 528 nm. The analytical curve was linear in the captopril concentration range from 1.0 Â 10 À5 to 5.0 Â 10 À4 mol l À1 with a detection limit of 8.0 Â 10 À6 mol l À1 . The relative standard deviation (RSD) was 0.35% (n ¼ 10) for a solution of 3.0 Â 10 À4 mol l À1 captopril solution, and an analytical frequency of 70 h À1 was obtained. The effects of excipients frequently found with captopril in pharmaceutical formulations, such as lactose, microcrystalline cellulose, starch, and magnesium stearate, were evaluated using the proposed flow-injection method. None of these substances caused significative interference 973 in the proposed method. The method was successfully applied to the determination of captopril in pharmaceutical products, and the results were compared with results obtained using a potentiometric method.

show abstract

Determinatin of captopril in biological fluids by gas-liquid chromatography

Cited by 54 publications

References 3 publications

Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases

Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases

Simultaneous determination of captopril and hydrochlorothiazide in human plasma by reverse-phase HPLC from linear gradient elution

Flow-Injection Spectrophotometric Determination of Captopril Exploiting Silver Chloranilate Solid-Phase Reactor

Contact Info

Product

Resources

About